Business Context and Reporting Period
Company: Atara Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2015
Event: Entry into a Material Definitive Agreement (Exercise of Option and Execution of License Agreement).
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
- Upfront Cash Payment: $4.5 million payable to Memorial Sloan Kettering Cancer Center (MSK).
- Contingent Payments: Up to $33.0 million in additional license fees and milestones (development, regulatory, and sales-related).
- Royalties: Escalating mid single-digit royalties on sales of Licensed Products.
Material Changes
On June 12, 2015, Atara exercised an option entered into in September 2014 with MSK. This action converted the option into an exclusive, worldwide license agreement for three clinical-stage allogenic T-cell therapy programs:
- T-cells activated against Epstein Barr Virus.
- T-cells activated against Cytomegalovirus.
- T-cells activated against Wilms Tumor 1.
MSK agreed to transfer certain investigational new drug applications (INDs) related to these products.
Outlook, Risks, and Contingencies
Management Obligations: Atara must use commercially reasonable efforts to commercialize the products and maintain active marketing efforts if commercialized.
Term: The agreement expires on a product-by-product and country-by-country basis, lasting until the later of patent expiration, market exclusivity expiration, or a specified number of years after the first commercial sale.
Post-Expiration Rights: Atara retains non-exclusive rights to the products upon expiration.
Termination Risks: MSK may terminate the agreement if Atara materially breaches the terms and fails to cure the breach within a specified period, or if Atara experiences certain insolvency events.
Investor Verification Checklist
- Verify the impact of the $4.5 million upfront payment on Atara's current cash position and liquidity.
- Review the specific milestones required to trigger the up to $33.0 million in contingent payments.
- Confirm the status of the transferred investigational new drug applications (INDs) for the three T-cell programs.
- Monitor the upcoming Form 10-Q for the quarter ending June 30, 2015, for the full text of the License Agreement and any Confidential Treatment Requests.